Role of telemedicine in the management of oral anticoagulation in atrial fibrillation: a practical clinical approach
| Autor: | Vivencio Barrios, Sergio Cinza-Sanjurjo, Javier García-Alegría, Román Freixa-Pamias, Frederic Llordachs-Marques, Carlos A Molina, Amparo Santamaría, David Vivas, Carmen Suárez Fernandez |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Barrios V] Department of Cardiology, Ramón y Cajal University Hospital, Alcalá University, Madrid, Spain. [Cinza-Sanjurjo S] Family Medicine, Porto do Son Health Center, Santiago de Compostela Health Area, A Coruña, Spain. [García-Alegría J] Department of Internal Medicine, Costa del Sol Hospital, Marbella (Málaga), Spain. [Freixa-Pamias R] Department of Cardiology, Moisés Broggi Hospital, Sant Joan Despí, Barcelona, Spain. [Llordachs-Marques F] Expert consultant in E-Health/Telemedicine, Founder at Doctoralia and CEO at Doctomatic, Barcelona, Spain. [Molina CA] Servei de Neurologia, Unitat d’Ictus, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
vitamin K antagonist
Medicació oral Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Anticoagulants [CHEMICALS AND DRUGS] Health Services Administration::Patient Care Management::Delivery of Health Care::Telemedicine [HEALTH CARE] enfermedades cardiovasculares::enfermedades cardíacas::arritmias cardíacas::fibrilación atrial [ENFERMEDADES] Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Administration Oral direct oral anticoagulant Other subheadings::Other subheadings::/drug therapy [Other subheadings] administración de los servicios de salud::gestión de la atención al paciente::prestación sanitaria::telemedicina [ATENCIÓN DE SALUD] Anticoagulants (Medicina) - Ús terapèutic terapéutica::farmacoterapia::vías de administración de medicamentos::administración oral [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Atrial Fibrillation Humans anticoagulation COVID-19 Anticoagulants Fibril·lació auricular - Tractament Telemedicina acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos hematológicos::anticoagulantes [COMPUESTOS QUÍMICOS Y DROGAS] Telemedicine Stroke Therapeutics::Drug Therapy::Drug Administration Routes::Administration Oral [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Molecular Medicine telemedicine Cardiology and Cardiovascular Medicine Cardiovascular Diseases::Heart Diseases::Arrhythmias Cardiac::Atrial Fibrillation [DISEASES] |
| Zdroj: | Scientia |
| Popis: | COVID-19; Direct oral anticoagulant; Telemedicine COVID-19; Anticoagulante oral directo; Telemedicina COVID-19; Anticoagulant oral directe; Telemedicina Compared with face-to-face consultations, telemedicine has many advantages, including more efficient use of healthcare resources, partial relief of the burden of care, reduced exposure to COVID-19, treatment adjustment, organization of more efficient healthcare circuits and patient empowerment. Ensuring optimal anticoagulation in atrial fibrillation patients is mandatory if we want to reduce the thromboembolic risk. Of note, telemedicine is an excellent option for the long-term management of atrial fibrillation patients. Moreover, direct oral anticoagulants may provide an added value in telemedicine (versus vitamin K antagonists), as it is not necessary to monitor anticoagulant effect or make continuous dosage adjustments. In this multidisciplinary consensus document, the role of telemedicine in anticoagulation of this population is discussed and practical recommendations are provided. V Barrios has received consultancy/lecture fees from Bayer, BMS/Pfizer, Boehringer Ingelheim and Daiichi Sankyo. S Cinza-Sanjurjo has received honoraria for presentations from Bayer, Boehringer-Ingelheim, Daiichi Sankyo and Pfizer-BMS; advisory board fees from Bayer, Boehringer-Ingelheim, Daiichi Sankyo and Pfizer-BMS; and funding for studies from Bayer. J García-Alegría reports consulting fees and/or lectures honoraria from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Daiichi Sankyo. R Freixa-Pamias has received honoraria for presentations from Bayer, Boehringer-Ingelheim, Daiichi Sankyo and Pfizer-BMS. F Llordachs-Marques. No potential conflicts of interest were declared by the author. CA Molina reports consulting fees and/or honoraria from Novo Nordisk, Bayer, Pfizer, BMS, Daiichi Sankyo and Boehringer Ingelheim. A Santamaría has received honoraria per conferences from Octapharma, Novo Nordisk, Bayer, Pfizer, BMS, Sobi, Shire, Sanofi, LEO Pharma, Rovi, Daiichi Sankyo, Werfen and Ferrer. D Vivas reports no potential conflicts of interest were declared by the author. C Suárez has received speaker and/or advisory fees from Bayer, Pfizer/BMS, Daiichi Sankyo. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|